Trius to Present at 7th Anti-Infectives Partnering and Deal-Making Summit

Oct 06, 2010, 16:00 ET from Trius Therapeutics, Inc.

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that Karen Joy Shaw, Ph.D., Senior Vice President of Biology at Trius Therapeutics, will present at the 7th Anti-Infectives Partnering and Deal-making Summit taking place in Boston October 7-8, 2010.  The presentation, titled "Torezolid: The Second Generation," will take place at 10:50 a.m. ET on October 8.

More information on the conference is available at

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit

SOURCE Trius Therapeutics, Inc.